Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial |
| |
Authors: | JUSTIN L. GRODIN,JAVED BUTLER,MARCO METRA,G. MICHAEL FELKER,ADRIAAN A. VOORS,JOHN J. MCMURRAY,PAUL W ARMSTRONG,ADRIAN F. HERNANDEZ,CHRISTOPHER O CONNOR,RANDALL C. STARLING,W.H. WILSON TANG |
| |
Affiliation: | 1. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas;2. Department of Medicine, University of Mississippi, Jackson, Mississippi;3. Department of Cardiology, University of Brescia, Brescia, Italy;4. Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina;5. Hanzeplein 1, University Med Center Groningen, Groningen, The Netherlands;6. University of Glasgow, Glasgow, United Kingdom;7. Department of Cardiology, University of Alberta, Edmonton, Canada;8. Inova Heart and Vascular Institute, Falls Church, Virginia;9. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. |
| |
Abstract: | BackgroundCirculating cardiac troponin levels (cTn), representative of myocardial injury, are commonly elevated in heart failure (HF) and related to adverse clinical events. However, whether cTn represents a spectrum of risk in HF is unclear.MethodsBaseline, 48–72-hour, and 30-day plasma cTnI was measured with the use of a new highly sensitive assay in 900 subjects with acute decompensated HF (ADHF) in ASCEND-HF. Multivariable models determined the relationship between cTnI and outcomes.ResultsThe median (interquartile range) cTnI was 16.4 (9.3–31.6) ng/L at baseline, 14.1 (7.8–29.7) ng/L at 48–72 hours, and 11.6 (6.8–22.5) ng/L at 30 days. After additional adjustment for N-terminal pro–B-type natriuretic peptide (NT-proBNP) to established risk predictors, both baseline (odds ratio [OR] 1.25; P?=?.03) and 48–72-hour (OR 1.43; P?=?.001) cTnI were associated with higher risk for death or worsening HF before discharge. However, only cTnI at 30 days was associated with 180-day death (hazard ratio 1.25; P?=?.007). There were no curvilinear associations between changing cTnI and clinical outcomes.ConclusionsCirculating cTnI level was associated with clinical outcomes in ADHF, but these observations diminished with additional adjustment for NT-proBNP. Although they likely represent a spectrum of risk in ADHF, these findings question the implications of changing cTnI levels during treatment. |
| |
Keywords: | Reprint requests: W.H. Wilson Tang, MD 9500 Euclid Ave, Desk J3-4, Cleveland, OH 44195. Tel: (216) 444-2121 Fax: (216) 445-6165. |
本文献已被 ScienceDirect 等数据库收录! |
|